Trending: Johnson & Johnson Authorizes Repurchase of Up to $5 Billion in Stock
14 Setembro 2022 - 03:36PM
Dow Jones News
14:03 ET -- Johnson & Johnson is one of the most talked
about companies in the U.S. across all news items in the last 12
hours, according to Factiva data. The New Jersey-based drug company
said its board has authorized the repurchase of up to $5 billion in
stock and it doesn't expect to incur debt to fund the repurchases.
J&J also reaffirmed its 2022 adjusted operational sales growth
guidance of 6.5% to 7.5% and earnings per share at $10.65 to
$10.75. "With our strong cash flow and lowest level of net debt in
five years, we have the ability to invest in innovation, grow our
dividend, execute strategic acquisitions, and take this action to
deliver shareholder returns and drive long-term growth," said CEO
Joaquin Duato. Dow Jones & Co. owns Factiva.
(jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
September 14, 2022 14:21 ET (18:21 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024